Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study

Richard R. Rubin, Yong Ma, Mark Peyrot, David G. Marrero, David W. Price, Elizabeth Barrett-Connor, William C. Knowler

    Research output: Contribution to journalArticle

    Abstract

    OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

    Original languageEnglish (US)
    Pages (from-to)2549-2551
    Number of pages3
    JournalDiabetes Care
    Volume33
    Issue number12
    DOIs
    StatePublished - Dec 2010

    Fingerprint

    Antidepressive Agents
    Medicine
    Outcome Assessment (Health Care)
    Life Style
    Placebos
    Metformin
    Research Design
    Pharmaceutical Preparations

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Advanced and Specialized Nursing

    Cite this

    Rubin, R. R., Ma, Y., Peyrot, M., Marrero, D. G., Price, D. W., Barrett-Connor, E., & Knowler, W. C. (2010). Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care, 33(12), 2549-2551. https://doi.org/10.2337/dc10-1033

    Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. / Rubin, Richard R.; Ma, Yong; Peyrot, Mark; Marrero, David G.; Price, David W.; Barrett-Connor, Elizabeth; Knowler, William C.

    In: Diabetes Care, Vol. 33, No. 12, 12.2010, p. 2549-2551.

    Research output: Contribution to journalArticle

    Rubin, RR, Ma, Y, Peyrot, M, Marrero, DG, Price, DW, Barrett-Connor, E & Knowler, WC 2010, 'Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study', Diabetes Care, vol. 33, no. 12, pp. 2549-2551. https://doi.org/10.2337/dc10-1033
    Rubin, Richard R. ; Ma, Yong ; Peyrot, Mark ; Marrero, David G. ; Price, David W. ; Barrett-Connor, Elizabeth ; Knowler, William C. / Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. In: Diabetes Care. 2010 ; Vol. 33, No. 12. pp. 2549-2551.
    @article{c94f69280a7c47b58b698002a947c3df,
    title = "Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study",
    abstract = "OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95{\%} CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.",
    author = "Rubin, {Richard R.} and Yong Ma and Mark Peyrot and Marrero, {David G.} and Price, {David W.} and Elizabeth Barrett-Connor and Knowler, {William C.}",
    year = "2010",
    month = "12",
    doi = "10.2337/dc10-1033",
    language = "English (US)",
    volume = "33",
    pages = "2549--2551",
    journal = "Diabetes Care",
    issn = "1935-5548",
    publisher = "American Diabetes Association Inc.",
    number = "12",

    }

    TY - JOUR

    T1 - Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study

    AU - Rubin, Richard R.

    AU - Ma, Yong

    AU - Peyrot, Mark

    AU - Marrero, David G.

    AU - Price, David W.

    AU - Barrett-Connor, Elizabeth

    AU - Knowler, William C.

    PY - 2010/12

    Y1 - 2010/12

    N2 - OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

    AB - OBJECTIVE - To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS - DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS - Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS - Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.

    UR - http://www.scopus.com/inward/record.url?scp=78349290872&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=78349290872&partnerID=8YFLogxK

    U2 - 10.2337/dc10-1033

    DO - 10.2337/dc10-1033

    M3 - Article

    C2 - 20805256

    AN - SCOPUS:78349290872

    VL - 33

    SP - 2549

    EP - 2551

    JO - Diabetes Care

    JF - Diabetes Care

    SN - 1935-5548

    IS - 12

    ER -